Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Founded in 1961, Mylan Laboratories is one of the largest US generic drug manufacturers. It is the sixth-largest generic manufacturer in the world. Its operations are very much based in the eastern USA; to this point, the company has had no significant presence in overseas markets. The company had ten ANDAs approved in 2006 and a further 21 so far in 2007.

In 2007, Mylan is due to acquire the generic businesses of Merck KgaA, for 4.9 billion euros (around US$6.7 billion). This is one of the largest generic sector mergers to date, and will transform Mylan from a US-based to a global company. Subject to regulatory clearances, the deal should be complete towards the end of 2007.

Generics are manufactured by Mylan Pharmaceuticals, based in Morgantown, West Virginia. Recent product launches in the US include fluconazole and ciprofloxacin. Mylan was also one of the first companies to bring a generic version of omeprazole to the US market.

In August 2006, Mylan announced the purchase of a majority stake in Matrix Laboratories, for around US$736 million. Matrix is an Indian company with a presence in Europe through its Docpharma subsidiary. The deal was completed in January 2007.